France
· Delayed Price · Currency is EUR Neovacs Statistics
Total Valuation
Neovacs has a market cap or net worth of EUR 3,613. The enterprise value is 252,622.
| Market Cap | 3,613 |
| Enterprise Value | 252,622 |
Important Dates
The next estimated earnings date is Wednesday, April 30, 2025.
| Earnings Date | Apr 30, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Neovacs has 269,590 shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 269,590 |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.00 |
| PB Ratio | 0.00 |
| P/TBV Ratio | 0.00 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.01 |
| EV / Sales | 0.31 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.15 |
Financial Position
The company has a current ratio of 0.66, with a Debt / Equity ratio of 0.03.
| Current Ratio | 0.66 |
| Quick Ratio | 0.61 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.29 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -104.43% and return on invested capital (ROIC) is -12.15%.
| Return on Equity (ROE) | -104.43% |
| Return on Assets (ROA) | -8.42% |
| Return on Invested Capital (ROIC) | -12.15% |
| Return on Capital Employed (ROCE) | -17.13% |
| Revenue Per Employee | 37,429 |
| Profits Per Employee | -1.61M |
| Employee Count | 22 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -100.00% in the last 52 weeks. The beta is -190.36, so Neovacs's price volatility has been lower than the market average.
| Beta (5Y) | -190.36 |
| 52-Week Price Change | -100.00% |
| 50-Day Moving Average | 0.06 |
| 200-Day Moving Average | 14.83 |
| Relative Strength Index (RSI) | 23.72 |
| Average Volume (20 Days) | 1,228,778 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Neovacs had revenue of EUR 823,434 and -35.45 million in losses.
| Revenue | 823,434 |
| Gross Profit | -2.74M |
| Operating Income | -6.79M |
| Pretax Income | -36.48M |
| Net Income | -35.45M |
| EBITDA | -5.93M |
| EBIT | -6.79M |
| Earnings Per Share (EPS) | n/a |
Balance Sheet
The company has 231,611 in cash and 480,623 in debt, giving a net cash position of -249,012 or -0.92 per share.
| Cash & Cash Equivalents | 231,611 |
| Total Debt | 480,623 |
| Net Cash | -249,012 |
| Net Cash Per Share | -0.92 |
| Equity (Book Value) | 18.63M |
| Book Value Per Share | n/a |
| Working Capital | -1.45M |
Cash Flow
In the last 12 months, operating cash flow was -1.47 million and capital expenditures -218,922, giving a free cash flow of -1.68 million.
| Operating Cash Flow | -1.47M |
| Capital Expenditures | -218,922 |
| Free Cash Flow | -1.68M |
| FCF Per Share | -6.25 |
Margins
| Gross Margin | n/a |
| Operating Margin | -825.06% |
| Pretax Margin | -4,429.97% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Neovacs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -981,217.58% |
| FCF Yield | -46,626.46% |
Stock Splits
The last stock split was on December 5, 2024. It was a reverse split with a ratio of 0.0001.
| Last Split Date | Dec 5, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.0001 |
Scores
Neovacs has an Altman Z-Score of -2.43. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.43 |
| Piotroski F-Score | n/a |